Application of traditional Chinese medicine composition in preparation of medicine for treating or preventing bacterial pneumonia

Abstract

The invention relates to application of a traditional Chinese medicine composition in preparation of a medicine for treating or preventing bacterial pneumonia. The traditional Chinese medicine composition comprises 1-3 parts of honey-fried ephedra, 1-10 parts of semen armeniacae amarae, 1-6 parts of platycodon grandiflorum, 1-6 parts of radix peucedani, 1-6 parts of thunberg fritillary bulb, 1-6 parts of radix stemonae, 1-3 parts of oroxylum indicum, 1-10 parts of radix glehniae and 1-3 parts of liquorice. The traditional Chinese medicine composition can obviously reduce leukocyte count and neutrophil of lipopolysaccharide induced pneumonia model rats, increase the percentage of lymphocytes and platelets, and has the effects of inhibiting body inflammatory response, removing antigens and promoting body recovery.

Description

Technical Field

[0001] The present invention relates to the field of disease treatment drugs, and more specifically, to the use of a traditional Chinese medicine composition in preparing drugs for treating or preventing bacterial pneumonia. Background Art

[0002] Bacterial pneumonia refers specifically to pneumonia caused by bacteria (such as Streptococcus pneumoniae and Staphylococcus aureus). Its main symptoms are roughly manifested in three aspects: First, fever, the body temperature can be as high as 39-40 degrees Celsius, and the elderly and weak patients may only have a low fever or no fever; second, cough, because inflammation has a large amount of inflammatory exudate in the terminal airways and alveoli of the lungs, which stimulates the respiratory system and causes coughing. In the early stage, it may be an irritating dry cough, followed by coughing up white mucus sputum or blood-streaked sputum; third, chest pain, because there are inflammatory secretions in the alveoli, which affects the ventilation function of the alveoli, and poor ventilation will cause chest pain, shortness of breath and other accompanying symptoms, which are often severe chest pain, needle-like, and worsen with coughing or deep breathing.

[0003] Traditional Chinese medicine has a long history and rich experience in treating bacterial pneumonia. Traditional Chinese medicine is often a combination of multiple herbal compound prescriptions with multi-faceted therapeutic effects. These herbs can simultaneously exert antibacterial, anti-inflammatory, expectorant, and immunomodulatory effects, which can help to fully relieve patients' symptoms and promote recovery. As the problem of drug resistance caused by the abuse of antibiotics becomes increasingly serious, the use of traditional Chinese medicine can reduce dependence on antibiotics to a certain extent. Traditional Chinese medicine treatment can be used as an auxiliary means to help improve efficacy and may reduce the amount and frequency of antibiotic use. Summary of the invention

[0004] The present invention aims to provide an application of a traditional Chinese medicine composition in the preparation of a medicine for treating or preventing bacterial pneumonia, wherein the traditional Chinese medicine composition comprises, by weight ratio, 1-3 parts of honey-roasted ephedra, 1-10 parts of bitter almonds, 1-6 parts of platycodon, 1-6 parts of peucedanum, 1-6 parts of thunbergii bulbs, 1-6 parts of stemona, 1-3 parts of oroxylum bungeana, 1-10 parts of northern adenophora, and 1-3 parts of liquorice.

[0005] Furthermore, the Chinese medicine composition includes: 1-1.5 parts of honey-roasted ephedra, 2-4 parts of bitter almonds, 1-3 parts of platycodon, 1-3 parts of peucedanum, 1-3 parts of thunbergii, 1-3 parts of stemona, 1-1.5 parts of oroxylum, 2-4 parts of northern adenophora, and 1-1.5 parts of liquorice.

[0006] Furthermore, the Chinese medicine composition includes: 1-1.5 parts of honey-roasted ephedra, 3-4 parts of bitter almonds, 1.5-2 parts of platycodon, 1.5-2 parts of peucedanum, 1.5-2 parts of thunbergii, 1.5-2 parts of stemona, 1-1.5 parts of oroxylum, 3-4 parts of northern adenophora, and 1-1.5 parts of liquorice.

[0007] Optionally, the Chinese medicine composition includes: 1 part of honey-roasted ephedra, 3.33 parts of bitter almonds, 2 parts of platycodon, 2 parts of peucedanum, 2 parts of thunbergii, 2 parts of stemona, 1 part of oroxylum, 3.33 parts of northern adenophora, and 1 part of licorice.

[0008] Among them, the raw materials used in the present invention can be directly ground into powder, or they can be extracts prepared by conventional means in the art; the composition can be directly ground into powder by traditional methods, or it can be an extract prepared by conventional means, so as to be made into different dosage forms, obtain better therapeutic effects and be more conducive to the preparation of modern drug dosage forms.

[0009] Specifically, the drug for treating or preventing bacterial pneumonia provided by the present invention is in an optional preparation form.

[0010] Furthermore, the preparation forms include tablets, capsules, pills, powders, granules, and pellets.

[0011] Preferably, the preparation method of the Chinese medicine composition as described above may include the following steps: adding 4-8 times the amount of 50%-80% ethanol to the four raw materials of honey-roasted ephedra, peucedanum, fritillaria thunbergii and stemonae, refluxing for 1-3 hours, filtering, and concentrating the filtrate under reduced pressure to obtain a clear paste; heating Platycodon grandiflorum, Glehnia littoralis, Oroxylum indica and Glycyrrhiza uralensis with water to boil, then adding bitter almonds and boiling, filtering, and concentrating the filtrate under reduced pressure to obtain a clear paste; combining the above two clear pastes and drying.

[0012] Furthermore, the preparation method of the Chinese medicine composition as described above may include the following steps: adding 6 times of 70% ethanol to ephedra, peucedanum, thunbergii and radix stemonae, refluxing for 2 hours, filtering, adding 4 times of 70% ethanol to the residues, refluxing for 2 hours, filtering, combining the filtrate, and concentrating under reduced pressure film to a relative density of 1.07 to obtain an alcohol-extracted clear paste; adding 10 times of water to bitter almond, northern adenophora, platycodon, licorice and oroxylum, boiling them and then adding bitter almond, boiling for 1.5 hours, filtering, adding 8 times of water to the residues, boiling for 1.5 hours, filtering, combining the filtrate, and concentrating under reduced pressure film to a relative density of 1.09 to obtain a water-extracted clear paste; combining the clear pastes, mixing them evenly, and drying.

[0013] The present invention also provides a method for preparing the aforementioned granules, which can be optionally: the dry powder prepared by any of the above composition preparation methods is mixed with 37%-41% dextrin and 1% aspartame, and dry granulated to obtain the granules.

[0014] The present invention also proposes the use of the Chinese medicine composition as described above in the preparation of a drug for treating or preventing pneumonia, wherein the Chinese medicine composition comprises: 1-3 parts of honey-fried ephedra, 1-10 parts of bitter almonds, 1-6 parts of platycodon grandiflorum, 1-6 parts of peucedanum, 1-6 parts of thunbergii, 1-6 parts of stemon, 1-3 parts of oroxylum, 1-10 parts of northern adenophora, and 1-3 parts of liquorice. The lung injury may be acute lung injury. The pneumonia refers to lipopolysaccharide-induced pneumonia.

[0015] Furthermore, the Chinese medicine composition includes: 1-1.5 parts of honey-roasted ephedra, 2-4 parts of bitter almonds, 1-3 parts of platycodon, 1-3 parts of peucedanum, 1-3 parts of thunbergii, 1-3 parts of stemona, 1-1.5 parts of oroxylum, 2-4 parts of northern adenophora, and 1-1.5 parts of liquorice.

[0016] Furthermore, the Chinese medicine composition includes: 1-1.5 parts of honey-roasted ephedra, 3-4 parts of bitter almonds, 1.5-2 parts of platycodon, 1.5-2 parts of peucedanum, 1.5-2 parts of thunbergii, 1.5-2 parts of stemona, 1-1.5 parts of oroxylum, 3-4 parts of northern adenophora, and 1-1.5 parts of liquorice.

[0017] Optionally, the Chinese medicine composition includes: 1 part of honey-roasted ephedra, 3.33 parts of bitter almonds, 2 parts of platycodon, 2 parts of peucedanum, 2 parts of thunbergii, 2 parts of stemona, 1 part of oroxylum, 3.33 parts of northern adenophora, and 1 part of licorice.

[0018] The beneficial technical effect of the present invention is that the present invention provides the use of a Chinese medicine composition in the preparation of a drug for treating bacterial pneumonia. The Chinese medicine composition of the present invention can significantly reduce the white blood cell count and neutrophil count of rats with lipopolysaccharide-induced bacterial pneumonia model, increase the percentage of lymphocytes and platelets, and has the effect of inhibiting the body's inflammatory response to clear antigens and promoting the body's recovery; it can significantly reduce the lung index of rats with lipopolysaccharide-induced bacterial pneumonia model, and has the effect of inhibiting lung inflammatory lesions, clearing silt and reducing swelling. Therefore, the Chinese medicine composition of the present invention has a good therapeutic effect on bacterial pneumonia. DETAILED DESCRIPTION

[0019] As mentioned above, the present invention aims to provide a use of a Chinese medicine composition in the preparation of a drug for bacterial pneumonia. The following will be described in detail in conjunction with the contents of the experimental examples.

[0020] It is particularly important to point out that similar substitutions and modifications made to the present invention are obvious to those skilled in the art, and they are all considered to be included in the present invention. Relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments.

[0021] If no specific conditions are specified in the present invention, all experiments were carried out under conventional conditions or conditions recommended by the manufacturer. Reagents or instruments used without specifying the manufacturer are conventional products that can be purchased commercially.

[0022] Example 1. Preparation of Chinese medicine compound granules

[0023] Raw materials: 100g of honey-roasted ephedra, 333g of bitter almond, 200g of platycodon, 200g of peucedanum, 200g of thunbergii, 200g of stemona, 100g of oroxylum, 333g of northern adenophora, and 100g of licorice.

[0024] Add 6 times of 70% ethanol to the medicinal materials (cooked pieces) such as ephedra, peucedanum, thunbergii and radix stemonae, reflux for 2 hours, filter, add 4 times of 70% ethanol to the medicinal residue, reflux for 2 hours, filter, combine the filtrate, and concentrate by vacuum film to a relative density of 1.07 (60°C) to obtain an alcohol-extracted clear paste, which is set aside for use. Add 10 times of water to the five medicinal materials (cooked pieces) such as bitter almond, northern adenophora, platycodon, licorice and oroxylum, boiled and added, boiled for 1.5 hours, filtered, add 8 times of water to the medicinal residue, boiled for 1.5 hours, filtered, combined the filtrate, and concentrated by vacuum film to a relative density of 1.09 (60°C) to obtain a water-extracted clear paste. Combine the clear pastes, mix well, spray dry, and obtain dry powder. Dextrin (37% to 41% of the theoretical yield of particles) and aspartame (1% of the theoretical yield of particles) were added to the dry powder, mixed evenly, dry granulated, and packaged with aluminum foil (4.0 g per bag) to obtain 1000 g of Xingbei cough granules.

[0025] Example 2: Effects on lipopolysaccharide-induced pneumonia in SD rats

[0026] Experimental Materials

[0027] Animals: 60 SD rats, SPF grade, male, 6-8 weeks old, weighing 180-200 g, purchased from Zhejiang Weitonglihua Experimental Animal Technology Co., Ltd.

[0028] Drug: Dexamethasone acetate tablets (batch number 2101142) Anhui Golden Sun Biochemical Pharmaceutical Co., Ltd.

[0029] Test drug: Chinese medicine composition, provided by Jiangsu Kangyuan Pharmaceutical Co., Ltd. Drug dosage: The daily dosage for humans is 52.99 g of crude drug, and the clinical dosage for adults (calculated as 70 kg) is 0.76 g of crude drug / kg. The equivalent dosage for rats is calculated to be 4.69 g of crude drug / kg. This dosage is set as the medium dosage, and the low, medium, and high dosage groups are set according to the dosage ratio of 0.5:1:2. The dosages are 2.345, 4.69, and 9.38 g of crude drug / kg, respectively, which are equivalent to 3.085, 6.17, and 12.34 times the clinical dosage, respectively.

[0030] Reagents: LPS: SIGMA, extracted from Escherichia coli O55:B5, batch number O00135218; dexamethasone acetate tablets Anhui Golden Sun Biochemical Pharmaceutical Co., Ltd., batch number 2101142.

[0031] Instruments: MULITSKAN Sky microplate reader (Thermo Fisher Scientific, USA), MINIP-2500 microplate centrifuge, MINI-4K microcentrifuge (Hangzhou Miou Instrument Co., Ltd.), 5418R low-temperature high-speed centrifuge (Eppendorf, Germany), fully automatic modular animal blood and body fluid analyzer Sysmex XN-1000, Sysmex Medical Electronics (Shanghai) Co., Ltd.

[0032] Experimental methods

[0033] 60 SD rats were randomly divided into 6 groups, 10 rats in each group, namely blank group, model group, positive control group, and low, medium and high dose groups of Chinese medicine composition. Except for the blank group and model group, which were given the same volume of pure water, the other groups were continuously gavaged for 2 days. One hour after the last administration, 10% chloral hydrate 0.35g / kg was injected intraperitoneally for anesthesia. After anesthesia, the rats were placed on a 45° flat plate, the tongue of the rats was pulled with forceps, 80μL of 5mg / kg LPS was sucked with a pipette, and dripped on the posterior wall of the rat's oral pharynx, and the rat's nose was pinched immediately. After 20s, the tongue and nose were released, and a slight tracheal rales appeared, which meant that the model was successful. The drug was continued for 3d after modeling.

[0034] Detection index: Rats were anesthetized with 10% chloral hydrate 0.35g / kg, 2mL of blood was collected from the abdominal aorta, and the WBC, NE, LY%, and PLT levels in the blood were measured using a Sysmex blood analyzer. The complete lung tissue was removed, the color and shape of the lungs were observed with the naked eye, and the lung index was determined by weighing.

[0035] The results show:

[0036] General condition: The rats in the blank group were in good condition, with normal activities, shiny fur, normal breathing, and normal diet. The rats in the model group had runny nose, reduced activities, weight loss, rapid breathing, dull hair and erect hair after modeling. Some rats had red noses, and pink secretions appeared in the noses of severe cases. After 3 days of treatment, the overall condition of the different drug administration groups was better than that of the model group, especially the medium and high dose groups of the Chinese medicine composition, which had more activities and more sensitive reactions.

[0037] In terms of rat white blood cell count, compared with the blank group, the WBC and NE levels of the model group rats were significantly increased (P < 0.01), and the LY% and PLT levels were significantly decreased (P < 0.01). Compared with the model group, the WBC and NE levels of the high-dose group of the Chinese medicine composition were significantly decreased (P < 0.01), and the LY% and PLT levels were significantly increased (P < 0.01). The NE level of the low-dose group of the Chinese medicine composition was significantly decreased (P < 0.01), and the LY% and PLT levels were significantly increased (P < 0.01). See Table 1 for details. White blood cell count (WBC) is the sum of white blood cells involved in inflammation and immune response. An increase in WBC level indicates that the body has an inflammatory response. When the body is invaded by pathogenic microorganisms, neutrophils (NE) migrate and aggregate to the site of inflammation and activate more immune cells. The lymphocyte percentage (LY%) is the proportion of lymphocytes in the total white blood cell count. Platelets (PLT) are a formed element in the blood and play an important role in wound healing, inflammatory response, thrombosis, hemostasis and other diseases and pathological processes. Infection may cause a decrease in PLT in the patient's body.

[0038] In terms of lung index, compared with the blank group, the lung index of the model group rats was significantly increased (P < 0.01). Compared with the model group, the lung index of the low, medium and high dose groups of the Chinese medicine composition was significantly decreased (P < 0.01), and there was a certain dosage trend. See Table 2 for details. The size of the lung index value indicates the severity of inflammatory lesions in the lungs. When inflammatory lesions occur in the lungs, weight gain will occur due to congestion and edema. Based on the above experimental results, the Chinese medicine composition has a certain therapeutic effect on lipopolysaccharide-induced bacterial pneumonia in rats.

[0039] Table 1 Effect on rat blood leukocyte count (n=10)

[0040]

[0041] Note: Compared with the blank control group, * P<0.05, ** P<0.01. Compared with the model group # P<0.05, ## P<0.01.

[0042] Table 2 Effects on rat lung index (n=10)

[0043]

[0044] Note: Compared with the blank control group, * P<0.05, ** P<0.01. Compared with the model group # P<0.05, ## P<0.01.

[0045] The above is only an exemplary description of the implementation method of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Use of a Chinese medicine composition in the preparation of a medicament for treating or preventing bacterial pneumonia, characterized in that: The traditional Chinese medicine composition comprises: 1-3 parts of honey-fried ephedra, 1-10 parts of bitter almond, 1-6 parts of platycodon, 1-6 parts of peucedanum, 1-6 parts of thunbergii, 1-6 parts of stemona, 1-3 parts of oroxylum, 1-10 parts of northern adenophora, and 1-3 parts of liquorice.

2. The use according to claim 1, characterized in that The traditional Chinese medicine composition comprises: 1-1.5 parts of honey-fried ephedra, 2-4 parts of bitter almonds, 1-3 parts of platycodon, 1-3 parts of peucedanum, 1-3 parts of thunbergii, 1-3 parts of stemona, 1-1.5 parts of oroxylum, 2-4 parts of northern adenophora, and 1-1.5 parts of liquorice.

3. The use according to claim 1, characterized in that The Chinese medicine composition comprises: 1 part of honey-roasted ephedra, 3.33 parts of bitter almonds, 2 parts of platycodon, 2 parts of peucedanum, 2 parts of thunbergii bulbs, 2 parts of stemona, 1 part of oroxylum bungeana, 3.33 parts of northern adenophora, and 1 part of liquorice.

4. The use according to any one of claims 1 to 3, characterized in that: The drug for treating or preventing bacterial pneumonia is in an optional preparation form.

5. The use according to claim 4, characterized in that: The preparation forms include tablets, capsules, pills, powders, granules and drop pills.

6. A use according to any one of claims 1 to 3, characterized in that: The preparation of the Chinese medicine composition comprises the following steps: Take four raw materials of honey-roasted ephedra, peucedanum, thunbergii and radix stemonae, add 4-8 times amount of 50%-80% ethanol, reflux for 1-3 hours, filter, and concentrate the filtrate under reduced pressure to obtain a clear paste; heat Platycodon grandiflorum, Glehnia littoralis, Oroxylum indica and licorice with water, then add bitter almonds and boil, filter, and concentrate the filtrate under reduced pressure to obtain a clear paste; combine the above two clear pastes, mix well and dry.

7. The use according to claim 6, characterized in that: The preparation of the traditional Chinese medicine composition comprises: adding 6 times of 70% ethanol to ephedra, peucedanum chinense, fritillaria thunbergii and stemonae, refluxing for 2 hours, filtering, adding 4 times of 70% ethanol to the residues, refluxing for 2 hours, filtering, combining the filtrate, concentrating under reduced pressure film to a relative density of 1.07, and obtaining an alcohol-extracted clear paste; adding 10 times of water to bitter almond, northern adenophora, platycodon, licorice and oroxylum, wherein the bitter almond is boiled and then added, boiling for 1.5 hours, filtering, adding 8 times of water to the residues, boiling for 1.5 hours, filtering, combining the filtrate, concentrating under reduced pressure film to a relative density of 1.09, and obtaining a water-extracted clear paste; combining the clear pastes, mixing evenly, and drying.

8. Use of a Chinese medicine composition in the preparation of a medicament for treating or preventing pneumonia, characterized in that: The traditional Chinese medicine composition comprises: 1-3 parts of honey-fried ephedra, 1-10 parts of bitter almond, 1-6 parts of platycodon, 1-6 parts of peucedanum, 1-6 parts of thunbergii, 1-6 parts of stemona, 1-3 parts of oroxylum, 1-10 parts of northern adenophora, and 1-3 parts of liquorice.

Images